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The ALSFRS as an outcome measure in therapeutic trials and its
relationship to symptom onset
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AMMAR AL-CHALABI2 & MARTIN R. TURNER1
1Nuffield Department of Clinical Neuroscience, University of Oxford and 2Department of Clinical Neuroscience,
Institute of Psychiatry, King’s College London, London SE5 8AF, UK
Abstract
The reduction in ALS Functional Rating Score (ALSFRS) from reported symptom onset to diagnosis is used to estimate
rate of disease progression. ALSFRS decline may be non-linear or distorted by drop-outs in therapeutic trials, reducing the
reliability of change in slope as an outcome measure. The PRO-ACT database uniquely allows such measures to be
explored using historical data from negative therapeutic trials. The decline of functional scores was analysed in 18 pooled
trials, comparing rates of decline based on symptom onset with rates calculated between interval assessments. Strategies to
mitigate the effects of trial drop-out were considered. Results showed that progression rate calculated by symptom onset
underestimated the subsequent rate of disability accumulation, although it predicted survival more accurately than four-
month interval estimates of dALSFRS or dFVC. Individual ALSFRS and FVC progression within a typical trial duration
were linear. No simple solution to correct for trial drop-out was identified, but imputation using dALSFRS appeared least
disruptive. In conclusion, there is a trade-off between the drive to recruit trial participants soon after symptom onset, and
reduced reliability of the ALSFRS-derived progression rate at enrolment. The need for objective markers of disease activity
as an alternative to survival-based end-points is clear and pressing.
Key words: Motor neuron disease, survival, prognosis, modelling; clinical trial
Introduction
ALS is a heterogeneous condition with multiple
pathological pathways culminating in overlapping
disease phenotypes (1). Despite this complexity,
clinical and demographic characteristics readily
assessed at time of presentation can inform predic-
tion of disease progression (2–7). However, even
within clinically-defined subtypes (8) or genotypes
(9,10), progression rates remain relatively dispersed.
Accurate characterization of multimodal biomarkers
that can capture the range of the pathogenic process
in ALS remains a priority (11).
The successful application of future therapies for
ALS depends upon meaningful evaluation against
valid and relevant outcome measures. Clinical
severity scores, whether measured by self-reported
loss of function scales (most commonly the revised
ALS Functional Rating Score, ALSFRS-R), or by
objective structured assessment (e.g. the Appel
Scale), have been reported to decline in a largely
linear fashion (12–14). Not all studies concur, in
particular early stages of the illness have been
characterized by accelerated functional decline
(15), although this effect is at least partially
mitigated by restricting analysis to a survivor sub-
group (7). The measured rate of decline remains an
important predictor of functional and mortality
outcomes (16,17). Change in ALSFRS over time
(dALSFRS) (Figure 7 in (18)) can serve as an
approximate measure of disease severity and cohort
studies have demonstrated dALSFRS to predict
survival (19), encouraging its inclusion as a covari-
ate in the analysis of interventional studies.
Irrespective of function, ventilatory failure is the
typical mode of death in ALS, and forced vital
capacity (FVC) measurement complements the
ALSFRS in both prediction of survival and repre-
sentation of disease progression (20–23).
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The self-reported date of symptom onset is a
critical framing heuristic in ALS that is taken as
time-zero for calculation of dALSFRS at the first
clinical encounter. This estimation is subject to
recall bias, and typically relies on perception of first
actual weakness, which can (albeit in a minority)
neglect onset in cognitive or respiratory domains
and more non-specific symptoms such as cramp or
fasciculation. dFVC may similarly be estimated at
the first clinical encounter by considering time-
dependent deviation from predicted FVC based
upon age, height and gender (13,24).
Repeated assessment of patients is inherent to
most clinical trials in ALS, and permits repeated
calculation of dALSFRS. Longitudinal analysis of
disability progression also serves to expose selective
withdrawal from trials of the most disabled partici-
pants. This potential confound is a complicating
factor in the interpretation of clinical trial outcomes
but prospective dALSFRS extrapolation may assist
to mitigate drop-out bias. Using pooled data from
therapeutic trials in ALS, we sought to compare
subjectively-reported symptom onset with that
calculated from repeated-interval derivations of
dALSFRS extrapolated backwards.
Methods
Demographic and clinical data from 17 therapeutic
trials comprising 4752 records in PRO-ACT were
included in the analysis on the basis of at least two
time-separated assessments of disability (25). The
majority of PRO-ACT records contain only original
ALSFRS, rather than revised (ALSFRS-R) scores.
Therefore, for harmonization, 882 records were
converted from ALSFRS-R to ALSFRS by collap-
sing across the respiratory subscore (discounting
orthopnoea). A total of 42,584 assessments across a
mean individual maximum time-span of 11.1 (5.4)
months were analysed, averaging 8.8 (3.6) assess-
ments per person.
Time elapsed from symptom onset was recorded
for over 99% of the included participants, thus
defining reported disease duration. The dALSFRS
(points decline per month) could therefore be
calculated as either drop in ALSFRS from 40
divided by disease duration, or by subtraction of
time-separated ALSFRS assessments divided by the
inter-visit time-interval. Calculated dALSFRS was
then used to extrapolate back to the date at which
ALSFRS ¼ 40, i.e. no disability.
This approach was then validated using FVC
data and ALSFRS-R scores. 4168 records in PRO-
ACT include at least two FVC measurements
separated by at least one month. The smaller
portion of PRO-ACT records with ALSFRS-R was
supplemented by 217 individual longitudinal data
records from the Lithium Carbonate in ALS
(LiCALS) study, resulting in 1709 individual
records suitable for analysis, that demonstrated
incremental disability over a median time-interval
of 11.0 months.
Within the PRO-ACT database 1863 individual
records included mortality data, and from this
subset only 464 remained alive at the last census.
Hazard curves were constructed from both the
entire population and the mortality subset to repre-
sent time-dependent risk of death or significant
disability (defined as ALSFRS 5¼ 21, the median
final assessment ALSFRS across participants).
Trial drop-out mitigation methods appraised
included the re-assignment of missing values with
either (1) imputed values of ALSFRS based on linear
extrapolation using dALSFRS calculated from the
first assessment to the last available assessment, or
(2) ALSFRS values carried forward unchanged from
the last available assessment for that participant, with
or without (3) assignment of ALSFRS ¼ 0 if the
participant died prior to the planned assessment.
Data were analysed using Matlab and SPSS 21.
Paired t-tests compared alternative measures for
individual patients and Spearman’s rho was used for
correlations to minimize the effect of non-normative
data. Mean value was followed by standard deviation
in parenthesis.
Results
At trial enrolment, the median length of disease
duration was 18.7 months (mean 22.5 (14.5)). The
mean rate of disease progression since symptom
onset was 0.59 (0.49) per month. A wide spread of
progression rate was noted, with positive skew
(Figure 1).
Averaging across participants the ALSFRS dropped
over each individual’s maximum-recorded interval
during the trial from 29.9 (5.7) to 21.2 (8.6) (Figure
2). This variability reflected both inter-individual
diversity in progression rates and inter-trial differences
in length of follow-up.
Longitudinal analysis was complicated by declin-
ing participation over time. Patients with less rapidly
progressive disease were increasingly over-represented
as follow-up extended. Global PRO-ACT ALSFRS
averages superficially suggested a deceleration in the
rate of disability accumulation in the later stages of
disease durations. However, analysis of progression
curves divided into sub-groups of survivors at pre-
defined yearly intervals, revealed a linear progression
(linear fit r2 ¼ 0.998, two-year survivor group) in
disability over the study period (Figure 3). Analysis of
the FVC data confirmed linear decline (r2 ¼ 0.992) in
respiratory function over time within survivor sub-
groups (Figure 4).
The apparent dramatic slowing in disability
accumulation in the later stages of ALS appeared
not to be a confounding feature specific to the
ALSFRS scale, but rather to be mediated by
2 M. Proudfoot et al.
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selective loss to the trial through death or with-
drawal of those with more rapidly progressive
disease. This interpretation was reinforced by
inspection of rates of disability accumulation as
calculated across intervals between trial assess-
ments. These rates remained constant within
subgroups of survivors to specified end-points
(Figure 5).
The rate of disease progression as measured
across each given individual’s maximum assessment
interval was also broad with positive skew, mean
0.95 (0.96) (Figure 6).
Considering the impact of including patient-
reported symptom onset data in the calculation of
disease progression rates, direct comparison was
possible in 4649 individuals for whom symptom
onset dates were available. This revealed the maximum
interval ALSFRS measurement-derived rate to be
faster (median difference 0.24 month1, mean 0.37
(0.93)) than that estimated by drop in ALSFRS from
symptom onset to trial enrolment (p50.001, t(4648)
¼ 27.10). A correlation was nonetheless still noted
between the rates as calculated by differing methods
(rho ¼ 0.421, p50.001).
Figure 1. The rate of disease progression in participants at the time of trial enrolment. Calculated as (40-enrolment ALSFRS)/months
from symptom onset.
Figure 2. The spread of disability levels as measured by ALSFRS at both the time of trial enrolment and at the last available time-point
(trial termination) for each individual.
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Excluding 354 individuals who did not accumu-
late any disability over the course of study parti-
cipation, the time-point of ALSFRS ¼ 40 was
estimated by extrapolating backwards from the final
assessment, using the rate of progression calculated
across the maximum assessment interval, under the
assumption of linearity. This estimated time-point
did not coincide precisely with reported symptom
onset (p 50.001). Functional disability severe
enough to register on the ALSFRS followed symp-
tom onset by a median lag of 5.8 months. This
interval between 1) the time-point that a patient first
perceived a motor abnormality, and 2) the temporal
estimation of when functional disability accumula-
tion was first detectable on the ALSFRS scale, was
found to be smaller the further into disease duration
that trial enrolment occurred (Figure 7). This
predictive accuracy was, however, also dependent
upon the individual’s rate of disease progression,
with the largest inaccuracy for those with slowest
disease progression (‘funnel’ appearance to scatter-
plot Figure 8).
The validation data analysis using the ALSFRS-
R described a decline from a median of 39 at trial
entry to 29 at final assessment. Disability accumu-
lation curves over time demonstrated a similar
Figure 3. Accumulation of disability over time appears to slow over the course of the trial (dotted line), but declining numbers of
participants are noted over time. Progression within groups of survivors to defined end-points appears more linear.
Figure 4. Decline in FVC mirrors ALSFRS in demonstrating apparent slowing across all participants but linear decline within survivor
sub-groups.
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flattening of progression rates, dependent on select-
ive loss to follow-up (Supplementary Figure 1). The
time-point of first significant disability milestone
(ALSFRS-R ¼ 48) was again estimated by back-
extrapolation from the final assessment point using
maximum interval dALSFRS-R. The median time-
lag from reported symptom onset was 8.3 months.
Disability accumulation, regardless of scale choice,
was subject to wide variability between individuals
(Supplementary Figure 2).
The median survival within the PRO-ACT
mortality subset was 32.4 months from symptom
onset, while median survival without significant
disability was 24.4 months. Ongoing active partici-
pation in the clinical trials was noted to decline
rapidly beyond 25 months after trial onset. In
accordance with the above findings, the risk of
acquiring significant disability appeared to plateau
and then decline (Figure 9). Restricting the hazard
ratio analysis to the survivor subset continued to
demonstrate a plateau in mortality risk at approxi-
mately 50 months after symptom onset. Mortality
was typically preceded by significant disability
(Figure 10). Both FVC and ALSFRS at the initial
visit were predictive of subsequent mortality, but
symptom onset-anchored initial rates of decline
Figure 5. The rate of disease progression during the trial (calculated between assessment intervals) does not alter if analysis restricted to
survivors. Including all participants (dotted line), the rate of disease progression appears to fall as more rapidly progressive patients drop
out.
Figure 6. The rate of disability accumulation over the course of the trial, ignoring the time-period from symptom onset to trial enrolment.
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improved predictive accuracy (strongest correlation
with survival was initial dALSFRS, rho ¼ 0.6, log-
log transform displayed), and still outperformed the
interval dALSFRS and dFVC derived over the first
four months of trial participation (Figure 11).
Comparative appraisal of drop-out mitigation
options revealed the last-observation-carried-for-
ward (LOCF) technique to only minimally correct
the apparent flattening in the dALSFRS slope,
whereas a more linear progression was revealed
using slope-imputed values (Figure 12). Assigning
ALSFRS ¼ 0 to assessments falling after the
confirmed date of a participant’s death resulted in
a disproportionate acceleration of apparent ALSFRS
decline unless the remaining absent values were re-
assigned by imputation or LOCF (Figure 13).
Discussion
The key findings of this study were:
 Initial rates of ALS progression calculated from
recalled date of symptom onset tended to
Figure 7. The time-difference (median ¼ 5.8 months) between reported symptom onset and our estimate of when ALSFRS ¼ 40 (based
on individual ALSFRS gradient during trial). Later enrolment allows more accurate prognostication for an individual, as more time has
passed for disability accumulation.
Figure 8. Predicting disease time-course from symptom onset. Within individuals with more rapidly progressive disease, using the
symptom onset to enrolment rate to predict disease duration was highly accurate. For individuals with slower disease progression, greater
inaccuracy is introduced.
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underestimate the subsequent rate of disability
progression.
 The recalled symptom onset-anchored rate of
progression nevertheless predicted survival
more accurately than four month interval esti-
mates of dALSFRS or dFVC.
 As the denominator of time was increased,
symptom onset-anchored progression rate
improved in its predictive power of future
progression rate.
 After comparatively slower initial progression
from symptom onset, individual ALSFRS and
FVC progression during a typical trial duration
appeared to be linear.
 No simple solution to correcting for trial drop-
out was identified, but imputation using
dALSFRS appeared least disruptive.
These findings are relevant for future studies that
intend to take account of dALSFRS in participant
enrolment, consideration of covariables, or end-
point selection. These data support the application
of the longest possible time-intervals as denominator
in calculation of dALSFRS to minimise chance
variation. These data also support previous findings
that the rate of disease progression calculated from
symptom onset carries valuable prognostic informa-
tion (13,16,18,19).
Figure 10. Hazard ratios for both disability and death appear to plateau despite restricting analysis to participants with mortality data at
census.
Figure 9. Hazard ratio of progression to significant disability (ALSFRS5¼ 21, the median final ALSFRS recorded) appears to plateau
and diminish with time. Complicated by declining trial participation.
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Significant discrepancy exists in the rate of disease
progression when calculated with or without the
initial time-point of reported symptom onset (26). It
seems probable that symptoms of ALS may be
noticeable by a patient (or family members, who
often contribute to the estimation of disease onset in
our experience) without causing any significant
disability. Therefore the ALSFRS might lack sensi-
tivity at the milder end of the disease spectrum.
Conversely, it may be that significant disability
milestones are rapidly attained in the middle stages
of ALS (i.e. around the time of enrolment in the trial)
without any acceleration of the disease process itself.
In the last stages of advanced disability, the ALSFRS
might well ‘bottom out’ (27), although most clinical
trials do not include these data; thus the imputation
choice of zero to represent death remains necessarily
arbitrary. FVC data correspondingly appeared to
change little in last months before death (23) and
were particularly prone to inaccuracy in the context
of significant bulbar weakness (28).
Progression and survival in ALS have been
modelled using a Weibull probability distribution
(17,29), but since longitudinally extensive data
Figure 13. Confirmed participant death can be acknowledged by assigning zero values to subsequent ALSFRS scores, resulting in spurious
apparent acceleration of disability progression. This effect is mitigated if other missing data (due to non-death trial withdrawal) are
imputed by slope or carried forward (LOCF).
Figure 12. Possible dropout mitigation strategies include last observation carried forward (LOCF) or imputation of the missing values
using prior dALSFRS. Imputation maintains linear progression of disability accumulation.
The ALSFRS as an outcome measure in therapeutic trials 9
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demonstrate a plateau effect in mortality risk
(Figure 8), previous investigators have resorted to
a compound distribution (30), suggesting this model
to have limited application. Untransformed data
clearly demonstrate prolonged survival in a minority
of patients (Figure 9).
Systematic reviews of prognostic factors in ALS
have been performed with respect to both survival
(31) and functional status (32). These factors
overlap but are not identical; however, reliable
models for prediction of function are limited by a
relative paucity of replicated studies (6,7). The
PRO-ACT database has already contributed greatly,
for example, in confirming that higher baseline
levels of serum urate and creatinine are independ-
ently associated with slower ALSFSR-R decline and
longer survival (25), and in the formulation of a
multivariate predictive model using Bayesian trees
(33). Historical accounts of long-term survival in
ALS noted a plateau in cumulative mortality around
five years from disease onset (2,30), and these
findings continue to be replicated in the modern era
(4,34–36). Mortality remains the gold standard
outcome measure for future ALS clinical trials, but
inclusion of novel measures of function has been
proposed (37) with the goal of addressing some of
the documented inadequacies of the ALSFRS-R
(38) and perhaps simultaneously accounting for the
confounding impact of mortality (29).
The ALSFRS has been reported to misjudge
disease severity when patients underestimate muscle
function in contrast to objective examination (39).
The relatively small time-span between assessments
in clinical trials is also perhaps more prone to
random error. It is also possible that cognitive
impairment might contribute to an inaccurate
recall of time-scale for symptom onset. The cogni-
tive profile of ALS is typified by behavioural,
executive and language dysfunction (40), but
impairment of memory is also reported (41), and
qualitatively distinct to that found in amnestic mild
cognitive impairment (42). Inaccuracy of recall
would adversely affect the prognostic value of
symptom onset calculations but should not result
in such systematically biased estimation of symptom
duration.
An important future consideration would be
whether rates of progression measured by alternative
tools might be less susceptible to this symptom onset
bias, thus potentially clarifying the bias inherent to
the ALSFRS scale itself. Such analyses should
include change in examination-based scales such
as staging (43) and neurophysiological indices such
as motor unit number estimation (MUNE), shown
to be sensitive to more slowly-progressive disease
(44). Alternative techniques to measure respiratory
function in ALS have been assessed to outperform
FVC in both sensitivity to detect deficits (45,46)
and prognostication (47). They may, however, share
some limitations (48,49), particularly since different
respiratory abnormalities do not evolve simultan-
eously and also partially respond to therapeutic
intervention (50).
This analysis meanwhile serves to remind of the
potential for measurement techniques to bias the
outcome of even the best-designed prospective
interventional studies and reinforces the need for
simultaneous assessment of more than one func-
tional outcome measure (20), corroborated by
multi-modal biomarker development (51).
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